Early clinical studies consistently showed blunted β-cell responsiveness to GIP in T2DM, reinforcing the belief that the hormone lacked translational potential and was unlikely to contribute meaningfully to metabolic therapy [8]. The gene discussed is GIP; the disease is type 2 diabetes mellitus.